Read/Post Comments (0) | Recommended this article (0)
Please login to Zacks.com or register to post a comment.
- Latest News
- Most Popular
- Hitting Home Runs & Grand Slams, Not Loud Outs
- RTI: Do Stocks Tank When QE Ends?
- 3 Top-Ranked Consumer ETFs to Buy Now
- This Week's Aggressive Growth Stocks
- Who Wants to Keep "Too Big to Fail" Alive?
- Debt-Ceiling Alarm Bell Tolls
- Avoid These 3 Eurozone ETFs This Summer
- RTI: When Will We Finally See a Pullback?
- Top Stocks with Big Potential Catch-Up Moves
- AWS 5/23: Is the Market Over-Reacting?
- PFP 5/23: Do No Harm
Recent Quotes
| No Recent Quote currently available |
My Portfolio
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
More Zacks Resources
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
Zacks #1 Stocks on the Move 05/23/2013
| Company Name | Symbol | %Change |
|---|---|---|
| WESTELL TECH | WSTL | 5.64% |
| MAXWELL TECH | MXWL | 3.33% |
| STEIN MART I | SMRT | 2.22% |
| SYNAPTICS IN | SYNA | 2.21% |
| DAWSON GEOPH | DWSN | 2.04% |
Quick Links
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
Charles River Laboratories International Inc. ( CRL - Snapshot Report ) reported first quarter 2012 earnings (excluding special items) of 70 cents per share, above the Zacks Consensus Estimate of 65 cents, and 14.8% above the year-ago earnings of 61 cents. Earnings were boosted by a lower share count.
The company’s quarterly revenue of $286 million remained flat year over year. Higher sales in Research Models and Services (RMS) segment was offset by a decline in Preclinical Services (PCS) segment sales and foreign exchange (Fx) translation. Revenues came in line with the Zacks Consensus Estimate.
Quarter in Detail
Charles Riveroperates through two segments - RMS and PCS.
Revenue from the RMS segment was $183.2 million in the first quarter, up 5.6% from the prior-year period. Segment revenue was boosted by strong sales of In Vitro and Avian products and RMS services. Excluding the 0.9% loss from Fx, RMS segment revenue moved up 6.5% year over year.
Revenue from the PCS segment was $102.8 million in the first quarter, down 8.6% from the prior-year period (down 7.6% excluding the negative impact of Fx). Unfavorable sales mix and lower biopharmaceutical services (BPS) sales adversely affected revenue performance.
During the first quarter of 2012, Charles River repurchased shares worth $12.5 million and has $103.8 million remaining under its $750 million repurchase program.
Outlook for 2012
Charles River reiterated its 2012 adjusted earnings guidance range of $2.60–$2.70 per share, provided earlier in December 2011. The Zacks Consensus Estimate of $2.68 per share is toward the higher end of the company’s guidance range. Net sales are expected to grow in the range of 0% - 2%, with a negative Fx impact of approximately 1%.
Our Recommendation
We currently have a Neutral recommendation on Charles River. The stock carries a Zacks #3 Rank, which translates into a short-term Hold rating.
Despite the consistent performance of the RMS segment, the PCS business fails to show any definite sign of recovery, thus keeping us on the sidelines.
Read the full reports :
Snapshot Report on CRL